Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2014

View Archived Issues

Merck & Co. patents new Hdm2 inhibitors for cancer

DemeRx synthesizes novel nAChR antagonists for pain and addictions

FDA approves Medac's autoinjectable subcutaneous methotrexate product

Scientists at Zenith Epigenetics disclose new BET bromodomain inhibitors

Gilead Sciences enrolls patients in phase Ib trial of GS-9857 in HCV

Merck & Co. to begin phase I trial of MK-8189

XMetA demonstrates efficacy in animal models of diabetes

Enrollment begins in phase I study of KHK-2823 in AML or myelodysplastic syndrome

FDA responds to Salix's appeal regarding Relistor sNDA

Researchers at Merck & Co. prepare novel glucokinase activators

Compugen identifies new immunomodulatory proteins

Researchers at Vertex design novel FimH inhibitors

Results of a first-in-human study of Axon's novel tau vaccine

Merck & Co. presents new SYK inhibitors

Gilead divulges novel PI3Kdelta inhibitors

NPT-088, a dimeric fusion protein for the treatment of AD

FDA grants orphan drug status to siponimod for dermatomyositis

Aerie initiates phase III registrational program for Rhopressa in glaucoma

G-Pen shows promising results in a phase II trial

FDA grants priority review to Avastin sBLA

Alcobra completes enrollment in phase III trial of MDX for adult ADHD

Anthera acquires Sollpura from Lilly

Clementia initiates phase II study of palovarotene for FOP

TauRx achieves target enrollment in first phase III study of LMTX for Alzheimer's

Targacept reports topline results from phase IIb study of TC-1734

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...